Minimally invasive procedures are often explored before surgical interventions are considered
A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure
Individual timelines vary based on dose escalation speed, baseline gut sensitivity, and overall digestive health
As for duration, researchers have found no observable adverse effects in test subjects being administered IGF-1 for periods between two to twelve weeks [8, 19]
Most studies involve small sample sizes, short durations, or lack control groups, which hampers the ability to draw definitive conclusions